Review highlights how tetramethylpyrazine modulates airway inflammation and remodeling in bronchial asthma, suggesting potential for improved patient outcomes.
Bronchial Asthma, characterized by chronic airway inflammation and remodeling, poses significant clinical challenges. Long-term use of conventional therapies often leads to metabolic complications and drug resistance. The bioactive alkaloid Tetramethylpyrazine, derived from Ligusticum chuanxiong Hort. (Apiaceae), demonstrates multi-target therapeutic potential through pathway modulation. TMP restores Th1/Th2 and Th17/Treg immune balance via Gαs/cAMP/PKA and AMPK/NF-κB signaling while suppressing ORMDL3-mediated collagen deposition. Clinical evidence demonstrates effective symptom alleviation with minimal adverse effects, establishing TMP as a promising complementary strategy for asthma management.
No takes yet. Share an insight, caveat, or question.
Han et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: